Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 78

Results For "biotech"

910 News Found

AstraZeneca India appoints Ram Mudaliar as India lead of their CDI division
People | January 20, 2022

AstraZeneca India appoints Ram Mudaliar as India lead of their CDI division

Ram’s appointment follows the launch of the CDI India division in October 2021.


Lonza, Forbion, and BioGeneration to focus on manufacturing of small molecules
News | January 19, 2022

Lonza, Forbion, and BioGeneration to focus on manufacturing of small molecules

The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space


Dr Charles Woler is the new Chairman of Sygnature Discovery
People | January 17, 2022

Dr Charles Woler is the new Chairman of Sygnature Discovery

Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021


Evonik to build production plant for rhamnolipids in Slovakia
Biotech | January 14, 2022

Evonik to build production plant for rhamnolipids in Slovakia

The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years


ABL Bio collaborates with SANOFI for Parkinson’s antibody
Biotech | January 12, 2022

ABL Bio collaborates with SANOFI for Parkinson’s antibody

ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease


Covaxin booster neutralises Omicron and Delta variants: Study
News | January 12, 2022

Covaxin booster neutralises Omicron and Delta variants: Study

The study will be published on the pre-print server, medRXiv, shortly


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Wacker and Biosyntia to develop production process for sustainable biotin
Biotech | January 11, 2022

Wacker and Biosyntia to develop production process for sustainable biotin

The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report
News | January 10, 2022

Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report

Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma